Icotinib - Zhejiang Betta Pharma

Drug Profile

Icotinib - Zhejiang Betta Pharma

Alternative Names: BPI-2009; BPI-2009H; Conmana; Icotinib hydrochloride

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Beta Pharma
  • Developer Beta Pharma; Zhejiang Betta Pharma
  • Class 3-ring heterocyclic compounds; Alkynes; Antineoplastics; Crown ethers; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Brain metastases; Lung cancer; Nasopharyngeal cancer; Oesophageal cancer
  • Phase I Psoriasis
  • No development reported Pancreatic cancer

Most Recent Events

  • 23 Nov 2017 Phase I development in Non-small cell lung cancer is ongoing in USA
  • 21 Nov 2017 Betta Pharmaceuticals initiates a phase II trial in Non-small cell lung cancer (Neoadjuvant therapy, Adjuvant therapy) in China (NCT03349203)
  • 18 Nov 2017 Phase-II clinical trials in Lung cancer (First-line therapy) in China (PO) (NCT03346811)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top